Exudative age-related macular degeneration: Efficacy and limits of the different treatments;Dégénérescence maculaire liée à l'âge exsudative: Efficacité et limites des différents traitements

Journal Francais d'Ophtalmologie

Volumn 31, Issue 5, 2008, Pages

  Berdugo Polak, M ^a,b   Behar Cohen, F ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔTEL DIEU   (France)

Author keywords

AMD; Angiogenesis; Anti VEGF therapy; Diabetes; Neovessels

Indexed keywords

EID: 45249096454     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-5512(08)72475-6     Document Type: Review

References (114)

1. Schmidt-Erfurth UM, Pruente C. Management of neovascular age-related macular degeneration. Prog Retin Eye Res, 2007;26: 437-51.
2. Virgili G, Bini A. Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database Syst Rev, 2007;18: CD004763.
3. Pournaras CJ, Tsacopoulos M, Strommer K, Gilodi N, Leuenberger PM. Scatter photocoagulation restores tissue hypoxia in experimental vasoproliferative microangiopathy in miniature pigs. Ophthalmology,1990; 97:1329-33.
4. Hiscott P, Paraoan L, Choudhary A, Ordonez JL, Al-Khaier A, Armstrong DJ. Thrombospondin 1, thrombospondin 2 and the eye. Prog Retin Eye Res, 2006; 25:1-18.
5. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol, 2000;45:195-214.
6. Matsuda S, Harino S, Iwahashi Y, Nagaya C. [Long-term enlargement of laser photocoagulation scars after treatment of choroidal neovascularization]. Nippon Ganka Gakkai Zasshi, 2002;106:708-13.
7. Iranmanesh R, Reddy S, Peiretti E, Slakter JS. Macular hole formation following thermal laser photocoagulation in a patient with choroidal neovascular membrane and age-related macular degeneration. Ophthalmic Surg Lasers Imaging, 2006;37:423-4.
8. Tzekov R, Lin T, Zhang KM, Jackson B, Oyejide A, Orilla W, et al. Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci, 2006;47:377-85.
9. Schmidt-Erfurth U, Niemeyer M, Geitzenauer W, Michels S. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology, 2005;112:2061-9.
10. Oner A, Karakucuk S, Mirza E, Erkilic K. Electrooculography after photodynamic therapy. Doc Ophthalmol, 2005;111;83-6.
11. Ozdemir H, Karacorlu SA, Karacorlu M. Early optical coherence tomography changes after photodynamic therapy in patients with age-related macular degeneration. Am J Ophthalmol, 2006;141:574-6.
12. Français C, Colasse-marthelot V, Weber M. Dégé nérescence maculaire liée à L'ĝe. Réalités Ophtalmologiques, 2006; 127:7-10.
13. Group, V. I. P. T. S. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol, 2001;131:541-60.
14. Meads C, Hyde C. Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review. Br J Ophthalmol, 2004;88:212-7.
15. VIP Report No 5 Writing Committee. Verteporfin in Photodynamic Therapy: Report no. 5. Ophthalmology, 2004;111:2144.
16. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol, 2006;141:638-45.
17. Ergun E, Maar N, Ansari-Shahrezaei S, Wimpissinger B, Krepler K, Wedrich A, et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol,142:10-16.
18. Sutter FK, Kurz-Levin MM, Fleischhauer J, Bosch MM, Barthelmes D, Helbig H. Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). Klin Monatsbl Augenheilkd, 2006;223:376-8.
19. Leparmentier A, Arnaud C, Fournie P, Mathis A, Quintyn J C. [Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration]. J Fr Ophtalmol, 2007;30:155-60.
20. Soubrane G, Kuhn D, Oubraham H, Coscas G. [Photodynamic therapy]. J Fr Ophtalmol, 2002;25:753-5.
21. Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev, 2005;19:CD002030.
22. Gelisken F, Inhoffen W, Karim-Zoda K, Grisanti S, Partsch M, Voelker M, et al. Subfoveal hemorrhage after verteporfin photodynamic therapy in treatment of choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol, 2005;243:198-203.
23. Kotoula MG, Tsironi EE, Karabatsas CH, Chatzoulis DZ. Photodynamic therapy. Retina, 2005;25:102-3.
24. Doshi AB, Moshfeghi DM, Jack RL. Anaphylactoid reaction after verteporfin therapy. Am J Ophthalmol, 2005;140:936-7.
25. Haimovici R, Kramer M, Miller JW, Hasan T, Flotte TJ, Schomacker KT, et al. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Current Eye Research, 1997;16:83-90.
26. Gastaud P. [The role of surgery in the treatment of age-related macular degeneration]. J Fr Ophtalmol, 2003;26:872-5.
27. Blinder KJ, Shah GK, Thomas MA, Holekamp NM, Joseph DP, Grand MG, et al. Surgical removal of peripapillary choroidal neovascularization associated with age-related macular degeneration. Ophthalmic Surg Lasers Imaging, 2005;36:358-64.
28. Kamei M, Tano Y, Maeno T, Ikuno Y, Mitsuda H, Yuasa T. Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid. Am J Ophthalmol, 1996;121:267-75.
29. Childs AL, Bressler NM, Bass EB, Hawkins BS, Mangione CM, Marsh MJ, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: quality-of-life findings: SST report no. 14. Ophthalmology, 2004;111:2007-14.
30. Marcus DM, Peskin E, Maguire M, Weissgold D, Alexander J, Fine S, et al. The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. Am J Ophthalmol, 2004;138:818-28.
31. RAD study. A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Radiation Therapy for Age-related Macular Degeneration. Ophthalmology, 1999;106:2239-47.
32. Bellmann C, Unnebrink K, Rubin GS, Miller D, Holz FG. Visual acuity and contrast sensitivity in patients with neovascular age-related macular degeneration. Results from the Radiation Therapy for Age-Related Macular Degeneration (RAD-) Study. Graefes Arch Clin Exp Ophthalmol, 2003;24:968-74.
33. Marcus DM, Sheils W, Johnson MH, McIntosh SB, Leibach DB, Maguire A, et al. External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial. Arch Ophthalmol, 2001;119:171-80.
34. Mauget-Faysse M, Chiquet C, Milea D, Romestaing P, Gerard JP, Martin P, et al. Long term results of radiotherapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol, 1999;83:923-8.
35. Soubrane G, Souied E, Haddad W, Razavi S, Roquet W, Coscas G. [Alternative therapies for choroidal neovessels resulting from age-related macular degeneration]. J Fr Ophtalmol, 2003;26:876-8.
36. Park CH, Duker JS, Mainster MA, Puliafito CA, Reichel E. Transpupillary thermotherapy (TTT) of occult choroidal neovascularization: a retrospective, non-comparative case series of fifty-seven eyes. Semin Ophthalmol, 2001;16:66-9.
37. Ciulla TA, Walker JD, Fong S, Criswell MH. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol, 2004;15:211-20.
38. Liu M, Regillo CD. A review of treatments for macular degeneration: a synopsis of currently approved treatments and ongoing clinical trials. Curr Opin Ophthalmol, 2004;15:221-6.
39. Miyamoto N, Iossifov D, Metge F, Behar-Cohen F. Early effects of intravitreal triamcinolone on macular edema: mechanistic implication. Ophthalmology, 2006;113:2048-53.
40. Sears JE, Hoppe G. Triamcinolone acetonide destabilizes VEGF mRNA in Muller cells under continuous cobalt stimulation. Invest Ophthalmol Vis Sci, 2005;46:4336-41.
41. Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol, 2002;240:42-8.
42. Jonas JB, Kreissig I, Degenring RF. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration. Br J Ophthalmol, 2004;88:1557-62.
43. Jonas JB, He Z, King BL, Kuroki T, Opland DM, Suzuma K, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol, 2003;87:462-8.
44. Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev, 2005;57:2063-79.
45. Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res, 2006;38:218-45.
46. Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol, 2005;40:598-604.
47. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina, 2000;20:244-50.
48. Razavi S, Coscas G, Soubrane G. [Age related macular degeneration: a review of anti-angiogenic treatments]. J Fr Ophtalmol, 2002;25:747-52.
49. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol, 2003;121:667-73.
50. Edelman JL, Castro MR. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp Eye Res, 2000;71:523-33.
51. Proia AD, Hirakata A, McInnes JS, Scroggs MW, Parikh I. The effect of angiostatic steroids and beta-cyclodextrin tetradecasulfate on corneal neovascularization in the rat. Exp Eye Res, 1993;57:693-8.
52. Murata N, Yamaji T, Uchida M, Tsuboi H, Suzuki H Yamada M, et al. Suppression of laser-induced choroidal neovascularization by subconjunctival injection of 9alpha-fluoromedroxyprogesterone acetate (FMPA), an anti-angiogenic agent, in rats. Biol Pharm Bull, 2006;29:2410-4.
53. Abe K, Shiraki K, Yasunari T, Kohno T, Miki T. Peripapillary subretinal neovascularization in sarcoidosis: remission and exacerbation during oral corticosteroid therapy. Jpn J Ophthalmol, 2002;46:95-9.
54. Korobelnik JF, Cochereau I, Cohen SY, Coscas G, Creuzot-Garcher C, Devin F, et al. [How to perform intravitreal injections]. J Fr Ophtalmol, 2006;29:82-6.
55. Saidel MA, Berreen J, Margolis TP. Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am J Ophthalmol, 2005;140:1141-3.
56. Delyfer MN, Rougier MB, Hubschman JP, Aouizérate F, Korobelnik JF. Cytomegalovirus retinitis following intravitreal injection of triamcinolone: report of two cases. Acta Ophthalmol Scand, 2007;85:681-3.
57. Rhee DJ, Peck RE, Bermont J, Martidis A, Liu M, Chang J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol, 2006;90:999-1003.
58. Jea SY, Byon IS, Oum BS. Triamcinolone-induced intraocular pressure elevation: intravitreal injection for macular edema and posterior subtenon injection for uveitis. Korean J Ophthalmol, 2006;20:99-103.
59. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA, 2005;293:1509-13.
60. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
61. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol, 1999;293:865-81.
62. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology, 2005;112:1035-47.
63. Gragoudas ES, Adamis AP, Cinningham ETJ, Feinsod M, Guyer DR, VISION Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 2004;351:2805-16.
64. Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem, 1998;273:20556-67.
65. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina, 2002;22:143-152.
66. Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, et al. VEGF164-mediated inflammation is required for pathological, but not for physiological, ischemia-induced retinal neovascularization. J Exp Med, 2003;198:483-9.
67. Adamis AP, Altaweel M, Bressler NM, Cunningham ETJ, Davis MD, Goldbaum M, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology, 2006;113:23-8.
68. Kourlas H, Schiller DS. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin Ther, 2006;28:36-44.
69. Gonzales CR, V. I. S. I. O. N. Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina, 2005;25:815-27.
70. Hughes MS, Sang DN. Safety and Efficacy of combined pegaptanib/ bevacizumab intravitreal injection as a treatment for Age-Related Macular Degeneration. ARVO Abstracts, 2006:B648.
71. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, berleau L, Licko V, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 1251-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol, 1999;27:536-44.
72. Gillies MC. What we don't know about avastin might hurt us. Arch Ophthalmol, 2006;124:1478-9.
73. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci, 2005;46:726-33.
74. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology, 2005;112:1048-53.
75. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 2006;355:1419-31.
76. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med, 2006;355:1432-44.
77. Genentech Inc., South San Francisco, CA. Lucentis (ranibizumab) injection. Prescribing information. 2006.
78. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular agerelated macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol, 2006;124:1532-42.
79. Wong TY, Liew G, Mitchell, P. Clinical update: new treatments for age-related macular degeneration. The Lancet, 2007;370:204-6.
80. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LAJ, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol vis Sci, 2006;47:4569-78.
81. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina, 2006;26:1006-13.
82. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol, 2004;22:1198.
83. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature, 2005;438:937-45.
84. McNatt LG, Weimer L, Yanni J, Clark AF, Alcon laboratories, Inc. Angiostatic Activity of steroid in the chick embryo cam an rabbit cornea models of neovacularization. J Ocul Pharmacol Ther, 1999;15:413-23.
85. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv, 2004;1:99-114.
86. Soubrane G, Kuhn D, Oubraham H, Coscas G. Anecortave Acetate Administered as a Posterior Juxtascleral Injection for Subfoveal CNV in Age-Related Macular Degeneration (AMD) Clinical Results. EVER, 2002.
87. BenEzra D, Griffin BW, Maftzir G, Sharif NA, Clark AF. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci, 1997;38:1954-62.
88. Clark AF, Mellon J, Li XY, Ma D, Leher H, Apte R, et al. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci, 1999;40:2158-62.
89. Clark AF. AL-3789: a novel ophthalmic angiostatic steroid. Expert Opin Investig Drugs, 1997;6:1867-77.
90. Penn JS, Rajaratnam VS, Collier RJ, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci, 2001;42:283-90.
91. Saishin Y, Saishin Y, Takahashi K, Lima e Silva R, Hylton D, Rudge JS, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol, 2003;195:241-8.
92. Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology, 2006;113:1522.e1-1522.e14.
93. Maier P, unsoeld AS, Junker B, Martin G, Drevs J, Hansen LL, et al. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol, 2005;243:593-600.
94. Saeed RW, Varma S, Peng-Nemeroff T, Sherry B, Balakhaneh D, Huston J, et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med, 2005;201:1113-23.
95. Tanito M, Li F, Elliott MH, Dittmar M, Anderson RE. Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. Invest Ophthalmol Vis Sci, 2007;48:1900-5.
96. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A, 2006;103:19478-83.
97. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature, 2005;438:967-74.
98. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol, 2003;22:63-71.
99. Uno K, Bhutto IA, McLeod DS, Merges C, Lutty GA. Impaired expression of thrombospondin-1 in eyes with age related macular degeneration. Br J Ophthalmol, 2006;90:48-54.
100. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta, 2006;1765:178-88.
101. Zhou Y, Poczatek MH, Berecek KH, Murphy-Ullrich JE. Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun, 2006;339:633-41.
102. Vailhe B, Feige JJ. Thrombospondins as anti-angiogenic therapeutic agents. Curr Pharm Des, 2003;9:583-8.
103. Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol, 2004;137:615-24.
104. Campochiaro PA, Hackett SF. Ocular neovascularization: a valuable model system. Oncogene, 2003;22:6537-48.
105. Dulak J, loboda A, Jazwa A, Zagorska A, Dorler J, Alber H, et al. Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium, 2005;12:233-41.
106. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappa B-and AP-1-mediated matrix metalloproteinase-9 expression, and is inhibited by atorvastatin. J Biol Chem, 2006;281:15099-109.
107. Cruysberg LP, Franklin AJ, Sanders J, Self C, Yuan P, Csaky KG, et al. Effective transscleral delivery of two retinal antiangiogenic molecules: carboxyamidotriazole (CAI) and 2-methoxyestradiol (2ME2). Retina, 2005;25:1022-31.
108. Howard-Sparks M, Al-Ghananeem AM, Pearson AP, Crooks PA. Evaluation of O(3alpha)-, O(21)-di-(N(1)-methyloxy-carbonyl-2, 4-dioxo-5-fluoropyrimidinyl) 17alpha-hydroxy-5beta-pregnan-20-one as a novel potential antiangiogenic codrug. J Enzyme Inhib Med Chem, 2005;20:417-28.
109. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci, 2006;47:1149-60.
110. Lai YK, Shen WY, Brankov M, Lai CM, Constable IJ, Rakoczy PE. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther, 2002;9:804-13.
111. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology, 2006;113:14-22.
112. Van de Moere A, Sandhu SS, Kak R, Mitchell KW, Talks SJ. Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Ophthalmology, 2005;112:1896-903.
113. Arevalo JF, Mendoza AJ, Fernández CF. Indocyanine green-mediated photothrombosis with and without intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization in age-related macular degeneration: a pilot study. Retina, 2005;25:719-26.
114. Chakravarthy U, Soubrane G, Bandello F, Chong V, Creuzot-Garcher C, Dimitrakos SA, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol, 2006;90:1188-96.